Human astrocytoma U138MG cells express predominantly type-A endothelin receptor
- PMID: 8664342
- DOI: 10.1016/0167-4889(95)00202-2
Human astrocytoma U138MG cells express predominantly type-A endothelin receptor
Abstract
Endothelin-1 (ET-1) binding to human astrocytoma U138MG cells was time-dependent, and bound [125I]ET-1 was difficult to dissociate. The B(max) and Kd values of [125I]ET-1 binding were 70 fmol/mg and 0.07 nM, respectively. Interestingly, different from other astrocytoma cells and astrocytes, the U138MG cells expressed predominantly ETA receptor as shown by RT-PCR results and binding studies. ET-1, FR139317, BQ123, PD142893 and Ro46-2005 inhibited specific [125I]ET-1 binding with Ki values of 0.10, 0.53, 4.3, 22, and 320 nM, respectively. ETB selective ligands ET-3 and IRL1620 were much less potent. The inhibitory effects of antagonists BQ123 and PD142893 on [125I]ET-1 binding diminished following the incubation time. ET-1 binding caused a modest stimulation in phosphatidylinositol hydrolysis with an EC50 value of 24 nM. In comparison to the human U373MG cells, ET-1-induced receptor internalization in U138MG cells was less efficient with 42% of bound ET-1 internalized after 30 min of incubation. These results imply that human astrocytoma cells/astrocytes are able to express either ETA or ETB receptor under different pathophysiological conditions.
Similar articles
-
Endothelin receptor in human astrocytoma U373MG cells: binding, dissociation, receptor internalization.J Pharmacol Exp Ther. 1995 Jul;274(1):499-507. J Pharmacol Exp Ther. 1995. PMID: 7616437
-
Dissociation characteristics of endothelin ETA receptor agonists and antagonists.J Cardiovasc Pharmacol. 1995;26 Suppl 3:S380-4. J Cardiovasc Pharmacol. 1995. PMID: 8587421
-
Identification and characterization of type A endothelin receptors in MMQ cells.Mol Pharmacol. 1993 Aug;44(2):285-91. Mol Pharmacol. 1993. PMID: 8355666
-
ET-traps offer a potential therapeutic tool for use in different autoimmune diseases.Drug Discov Today. 2020 Jul;25(7):1142-1145. doi: 10.1016/j.drudis.2020.04.011. Epub 2020 Apr 20. Drug Discov Today. 2020. PMID: 32325125 Review.
-
Pharmacology and physiopathology of the brain endothelin system: an overview.Curr Med Chem. 2006;13(6):627-38. doi: 10.2174/092986706776055652. Curr Med Chem. 2006. PMID: 16529555 Review.
Cited by
-
Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma.Cancer Sci. 2006 Dec;97(12):1388-95. doi: 10.1111/j.1349-7006.2006.00333.x. Epub 2006 Oct 9. Cancer Sci. 2006. PMID: 17032313 Free PMC article.
-
The independent, unfavorable prognostic factors endothelin A receptor and chemokine receptor 4 have a close relationship in promoting the motility of nasopharyngeal carcinoma cells via the activation of AKT and MAPK pathways.J Transl Med. 2013 Aug 29;11:203. doi: 10.1186/1479-5876-11-203. J Transl Med. 2013. PMID: 23987636 Free PMC article.
-
Expression of endothelins and their receptors in glioblastoma cell lines.J Neurooncol. 2006 Aug;79(1):1-7. doi: 10.1007/s11060-005-9111-z. Epub 2006 Mar 24. J Neurooncol. 2006. PMID: 16557350
-
Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.Neuro Oncol. 2008 Aug;10(4):617-23. doi: 10.1215/15228517-2008-013. Epub 2008 May 13. Neuro Oncol. 2008. PMID: 18477765 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources